SpinalCyte announced the preliminary results of phase II animal studies for spinal disc height improvement.
Here are three things to know:
1. SpinalCyte is a tissue engineering technology company focused on developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts.
2. Howard An, MD, director, division of spine surgery and spine fellowship program at Rush University Medical Center in Chicago is the principal investigator of the studies, which began in 2014.
3. Dr. An's team is reporting a significant increase in disc height indexes in the discs treated with human dermal fibroblasts.